Evotec initiates ground-breaking for new biologics facility

The manufacturing facility in Toulouse is expectedto be operational in H2 2024

Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, France (EU), the second facility of its kind and the first one on European ground, will employ Just – Evotec Biologics’ flexible J.POD® technology to deliver much-needed clinical and commercial manufacturing capacity for biologics.

Preview of the new biologics manufacturing plant J.POD® Toulouse, France (EU); (Image: © Brunerie & Irissou Architectes, Thomas Brunerie)

Biologics are a highly effective therapeutic option with broad applicability across many indications. However, the traditional fed-batch manufacturing presents significant challenges, especially at the upscaling from clinical to commercial supply. With a modular continuous manufacturing setup, the J.POD® technology allows for highly intensified cGMP manufacturing of biologics at flexibly scalable quantities, thus reducing both scale-up risks and manufacturing costs significantly.

During a ceremony on Campus Curie, Jean-Luc Moudenc, President of Toulouse Métropole and Mayor of Toulouse, Jalil Benabdillah, Vice-President, Economy, Employment, Innovation and Reindustrialisation of the Occitania region as well as Étienne Guyot, Prefect of Haute-Garonne and Occitania, joined the management of Evotec and subsidiary company, Just – Evotec Biologics, to break ground for the new facility. J.POD® Toulouse, France (EU) is expected to be operational in H2 2024 and will create upwards of 150 new high-skill jobs on Evotec’s Campus Curie in Toulouse.

Just – Evotec Biologics opened the first facility of this kind, J.POD® Redmond, WA (US), in August 2021. The first manufacturing runs for valued partners, one of them being the U.S. Department of Defense, were initiated shortly thereafter.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “Today’s ground-breaking for J.POD® Toulouse, France (EU), Just – Evotec Biologics’ second J.POD® facility, marks an important milestone on our path to making biologics globally available. J.POD® is a disruptive technology that makes biologics manufacturing not only scalable, but even more importantly, available right where they are needed. We are grateful to be able to realise this project with funding from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture as well as Toulouse Métropole.”

The construction of J.POD® Toulouse, France (EU) benefits from French government funding as part of the Investments for the future Programme (programme d’investissements d’avenir in French) and is also supported economically by the Occitanie Region and Toulouse Métropole.

More News

Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …
Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus.
Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus. ( Picture: © Nico Michaelsen, Evotec SE)

Senator Dr. Melanie Leonhard visits Evotec

Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...

Read more …
For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. (Picture: © Evotec)

Evotec enters partnership with Hannover Medical School

Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...

Read more …